Opinion|Videos|November 27, 2024
Real-World Outcomes in HER2-Positive NSCLC
Key Takeaways
- Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment settings.
- Clinical trials involve selected patients, while real-world settings include those with comorbidities and varying performance statuses.
Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do real-world patient outcomes for patients with HER 2 positive NSCLC compare to those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
Across the US, Obesity Care Still Lacks an Owner
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5